Literature DB >> 11311998

Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.

R Borrow1, J Southern, N Andrews, N Peake, R Rahim, M Acuna, S Martin, E Miller, E Kaczmarski.   

Abstract

Few data are available on the kinetics of meningococcal serogroup C-specific antibody production following meningococcal serogroup C conjugate (MCC) vaccination, particularly in those who have received prior meningococcal A/C polysaccharide (MACP) vaccination(s). Laboratory staff who had previously received either one dose (n = 35), two doses (n = 18) of MACP vaccine or who were naïve to previous meningococcal vaccination (n = 42) were vaccinated with MCC. Bloods were taken pre-vaccination, on the subsequent 4 days and on days 10 and 28. Serogroup C serum bactericidal antibody (SBA), and anti-serogroup C-specific IgG, IgM and IgA were measured. There were no significant differences between the groups who had received either 2 or 1 prior dose(s) of MACP, therefore, these results were combined. Up to day 4 there was no evidence of a significant increase or decrease in the median levels of SBA, IgG, IgM or IgA in either the naïve or MACP groups, although about 20% of individuals did have 4-fold SBA rises by day 4. By day 10 there were large significant increases in the levels of SBA, IgG, IgM and IgA with respective fold increases from pre-vaccination levels of 4.6, 1.9, 1.2 and 2.1 in the MACP group and 270, 13.4, 4.8 and 33.8 in the naïve group. Further significant increases were seen between day 10 and 28 for SBA, IgG and IgM (naïve group only). By day 28, 4-fold SBA rises had occurred in 63.5% of the MACP group and 97.6% of the naïve group. The SBA GMT on day 28 significantly differed between the naïve and MACP groups with GMTs 2.8-fold higher in the naïve group (P = 0.021). In conclusion, no decline in serogroup C-specific antibody levels was demonstrated immediately post-MCC vaccination whilst these levels had risen significantly by day 10. Putative protective SBA titres (> or =8, 32 or 128) were observed by day 10 following MCC vaccination regardless of MACP history.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311998     DOI: 10.1016/s0264-410x(01)00050-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.

Authors:  J McVernon; P D R Johnson; A J Pollard; M P E Slack; E R Moxon
Journal:  Arch Dis Child       Date:  2003-05       Impact factor: 3.791

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.

Authors:  Changfa Cui; Rodney Carbis; So Jung An; Hyun Jang; Cecil Czerkinsky; Shousun C Szu; John D Clemens
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

4.  Observed parent-child relationship quality predicts antibody response to vaccination in children.

Authors:  Thomas G O'Connor; Hongyue Wang; Jan A Moynihan; Peter A Wyman; Jennifer Carnahan; Gerry Lofthus; Sally A Quataert; Melissa Bowman; Anne S Burke; Mary T Caserta
Journal:  Brain Behav Immun       Date:  2015-04-09       Impact factor: 7.217

5.  Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Tsegaye Alebel; Degu Berhanu; Morten Harboe; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

6.  Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.

Authors:  Jo Southern; Sarah Deane; Lindsey Ashton; Ray Borrow; David Goldblatt; Nick Andrews; Paul Balmer; Rhonwen Morris; J Simon Kroll; Elizabeth Miller
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

7.  Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.

Authors:  Paul Balmer; Michelle Falconer; Paula McDonald; Nick Andrews; Emily Fuller; Christine Riley; Edward Kaczmarski; Raymond Borrow
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.

Authors:  Shannon L Harris; Adam Finn; Dan M Granoff
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteria.

Authors:  Pablo A García-Ojeda; Sharon Hardy; Steven Kozlowski; Kathryn E Stein; Ian M Feavers
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.